

Vaskar Saha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3792353/publications.pdf>

Version: 2024-02-01

74
papers

3,597
citations

147801

31
h-index

138484

58
g-index

78
all docs

78
docs citations

78
times ranked

4458
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. <i>Lancet</i> , The, 2010, 376, 2009-2017.	13.7	282
2	Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. <i>Lancet Oncology</i> , The, 2012, 13, 936-945.	10.7	282
3	Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2012, 366, 1371-1381.	27.0	252
4	Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. <i>Journal of Clinical Oncology</i> , 2010, 28, 4755-4761.	1.6	203
5	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, e26-e37.	1.4	195
6	Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 843.	7.4	166
7	Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 8167-8172.	7.1	146
8	IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. <i>Blood</i> , 2014, 123, 1691-1698.	1.4	129
9	Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. <i>Blood</i> , 2011, 117, 1614-1621.	1.4	122
10	Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. <i>British Journal of Haematology</i> , 2005, 130, 67-75.	2.5	117
11	EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. <i>Blood</i> , 2016, 127, 2214-2218.	1.4	108
12	Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. <i>British Journal of Haematology</i> , 2002, 117, 821-827.	2.5	107
13	Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2016, 128, 911-922.	1.4	103
14	Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. <i>Blood</i> , 2011, 117, 6247-6254.	1.4	86
15	Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. <i>European Journal of Cancer</i> , 2015, 51, 218-224.	2.8	80
16	Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. <i>Lancet Haematology</i> , the, 2018, 5, e641-e652.	4.6	78
17	A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug l-asparaginase. <i>Journal of Clinical Investigation</i> , 2009, 119, 1964-73.	8.2	69
18	Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. <i>Haematologica</i> , 2018, 103, 107-115.	3.5	68

#	ARTICLE	IF	CITATIONS
19	TEL Deletion Analysis Supports a Novel View of Relapse in Childhood Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2004, 10, 5355-5360.	7.0	66
20	Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia. <i>Blood</i> , 2016, 128, 453-456.	1.4	60
21	Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003, 123, 100-102.	2.5	58
22	Philadelphia positive acute lymphoblastic leukaemia of childhood. <i>British Journal of Haematology</i> , 2005, 130, 489-500.	2.5	49
23	RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 638-649.	1.4	49
24	Chromatin Modification, Leukaemia and Implications for Therapy. <i>British Journal of Haematology</i> , 2002, 118, 714-727.	2.5	45
25	Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. <i>British Journal of Haematology</i> , 2005, 129, 35-44.	2.5	44
26	Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2005, 130, 26-35.	2.5	39
27	QUALIFIED PREDICTIONS FOR MICROARRAY AND PROTEOMICS PATTERN DIAGNOSTICS WITH CONFIDENCE MACHINES. <i>International Journal of Neural Systems</i> , 2005, 15, 247-258.	5.2	37
28	Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. <i>Lancet Haematology</i> , 2019, 6, e204-e216.	4.6	36
29	Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 43048-43064.	1.8	35
30	LISA: a web-based decision-support system for trial management of childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2005, 129, 746-754.	2.5	34
31	Acute lymphoblastic leukaemia cells produce large extracellular vesicles containing organelles and an active cytoskeleton. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1294339.	12.2	34
32	Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial. <i>PLoS ONE</i> , 2014, 9, e108107.	2.5	34
33	Expression profile of wild-type ETV6 in childhood acute leukaemia. <i>British Journal of Haematology</i> , 2003, 122, 94-98.	2.5	30
34	MEDICAL MANAGEMENT OF ASPERGILLUS FLAVISENDOCARDITIS. <i>Pediatric Hematology and Oncology</i> , 2000, 17, 425-427.	0.8	27
35	Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. <i>European Journal of Cancer</i> , 2021, 151, 175-189.	2.8	27
36	Protocol for ICiLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. <i>Trials</i> , 2022, 23, 102.	1.6	26

#	ARTICLE	IF	CITATIONS
37	Expression pattern and cellular distribution of the murine homologue of AF10. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1998, 1443, 285-296.	2.4	23
38	The cloning, mapping and expression of a novel gene, BRL, related to the AF10 leukaemia gene. <i>Oncogene</i> , 1999, 18, 7442-7452.	5.9	20
39	Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor. <i>Haematologica</i> , 2019, 104, e13-e16.	3.5	19
40	Cytogenetic and molecular evidence of marrow involvement in extramedullary acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2000, 110, 547-551.	2.5	18
41	Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia—a report from the UKALL 2011 trial. <i>European Journal of Cancer</i> , 2019, 120, 75-85.	2.8	18
42	Translocations, fusion genes, and acute leukemia. , 1998, 72, 264-276.		17
43	Anaplastic large cell lymphoma in childhood. <i>Medical and Pediatric Oncology</i> , 1993, 21, 665-670.	1.0	12
44	Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29046.	1.5	11
45	A triple- probe FISH screening strategy for risk-stratified therapy of acute lymphoblastic leukaemia in low-resource settings. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27366.	1.5	10
46	Development of a selected reaction monitoring mass spectrometry-based assay to detect asparaginyl endopeptidase activity in biological fluids. <i>Oncotarget</i> , 2016, 7, 70822-70831.	1.8	10
47	<i>AF6</i> gene on chromosome band 6q27 maps distal to the minimal region of deletion in epithelial ovarian cancer. <i>Genes Chromosomes and Cancer</i> , 1995, 14, 220-222.	2.8	9
48	Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India. <i>British Journal of Haematology</i> , 2019, 186, 861-865.	2.5	9
49	Microbiology, infection control and infection related outcome in pediatric patients in an oncology center in Eastern India: Experience from Tata Medical Center, Kolkata. <i>Indian Journal of Cancer</i> , 2014, 51, 415.	0.2	9
50	Mixed-phenotypic acute leukemia series from tertiary care center. <i>Indian Journal of Pathology and Microbiology</i> , 2017, 60, 43-49.	0.2	9
51	Routine blood counts in children with acute lymphoblastic leukaemia after completion of therapy: are they necessary?. <i>British Journal of Haematology</i> , 2003, 122, 451-453.	2.5	8
52	Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia. <i>Haematologica</i> , 2017, 102, 1075-1084.	3.5	8
53	The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis. <i>Health Economics Review</i> , 2019, 9, 40.	2.0	7
54	The Treatment of <i>Pseudomonas aeruginosa</i> Meningitis Old Regime or Newer Drugs?. <i>Scandinavian Journal of Infectious Diseases</i> , 1993, 25, 81-83.	1.5	5

#	ARTICLE	IF	CITATIONS
55	Increased radiosensitivity in a child with T-cell non-Hodgkin's lymphoma. , 1996, 27, 565-570.		5
56	Late-Onset Hemorrhagic Cystitis Following Bone Marrow Transplantation: A Case Report. Pediatric Hematology and Oncology, 1997, 14, 273-275.	0.8	5
57	SOX7 promotes the maintenance and proliferation of B cell precursor acute lymphoblastic cells. Oncotarget, 2017, 8, 64974-64983.	1.8	5
58	Molecular Characterization of AML1 (RUNX1) Amplification: A Poor Risk Chromosomal Marker in Acute Lymphoblastic Leukaemia (ALL).. Blood, 2004, 104, 140-140.	1.4	5
59	Gene BRI40, Which is Related to AF10 and AF17, Maps to Chromosome Band 3p25. Genes Chromosomes and Cancer, 1996, 17, 269-272.	2.8	4
60	Simplifying treatment for children with ALL. Lancet, The, 2007, 369, 82-83.	13.7	4
61	Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia. PLoS ONE, 2017, 12, e0178606.	2.5	4
62	Activity and toxicity of intramuscular 1000 μ m ² polyethylene glycolâ€E. coliâ€asparaginase in the UKALL 2003 and UKALL 2011 clinical trials. British Journal of Haematology, 2022, , .	2.5	3
63	An odyssey in search of a cure: The evolution of treatment of childhood acute lymphoblastic leukemia in the United Kingdom. Indian Journal of Pediatrics, 1993, 60, 525-538.	0.8	2
64	Long-Term Prednisolone Therapy in Children with Idiopathic Pulmonary Hemosiderosis. Pediatric Hematology and Oncology, 1993, 10, 89-91.	0.8	2
65	Response to Piel etâAal. British Journal of Haematology, 2004, 125, 412-412.	2.5	2
66	Molecular Techniques to Improve Outcome in Childhood ALL. , 2004, 91, 111-122.		1
67	Relapsed Acute Lymphoblastic Leukemia of Childhood. , 2017, , 255-297.		1
68	Reply to: Comment on: Unsatisfactory quality of E. coli asparaginase biogenerics in Indiaâ€Implications for clinical outcomes in acute lymphoblastic leukaemia. Pediatric Blood and Cancer, 2022, 69, e29334.	1.5	1
69	Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol. Blood, 2015, 126, 1414-1414.	1.4	1
70	Early Response to Induction Is Predictive of Survival in Childhood Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia: Results of the Medical Research Council ALL 97 Trial.. Blood, 2004, 104, 165-165.	1.4	1
71	Non-Hodgkin's Lymphomas of Childhood. , 2006, , 502-525.		1
72	Identifying Targets for New Therapies in Children with Acute Lymphoblastic Leukemia. , 2011, , 25-37.		0

#	ARTICLE	IF	CITATIONS
73	Induction Regimens in Acute Myeloid Leukemia. , 0, , 221-239.		0
74	Role of Maintenance Treatment in Childhood Acute Myeloid Leukemia. , 0, , 250-278.		0